Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?

Anti-programmed cell death (PD)-1/PD-ligand 1 (L1) therapies have significantly improved the outcomes for non-small cell lung cancer (NSCLC) patients in recent years. These therapies work by reactivating the immune system and enabling it to target cancer cells once more. There is a general agreement...

Descripción completa

Detalles Bibliográficos
Autores principales: Acheampong, Emmanuel, Spencer, Isaac, Lin, Weitao, Ziman, Melanie, Millward, Michael, Gray, Elin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678919/
https://www.ncbi.nlm.nih.gov/pubmed/31262041
http://dx.doi.org/10.3390/cancers11070920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678919/
https://www.ncbi.nlm.nih.gov/pubmed/31262041
http://dx.doi.org/10.3390/cancers11070920

Ejemplares similares